دورية أكاديمية
أعرض في EDS

Nanocarriers of shRNA-Runx2 directed to collagen IV as a nanotherapeutic system to target calcific aortic valve disease.

التفاصيل البيبلوغرافية
العنوان: Nanocarriers of shRNA-Runx2 directed to collagen IV as a nanotherapeutic system to target calcific aortic valve disease.
المؤلفون: Voicu G; 'Medical and Pharmaceutical Bionanotechnologies' Laboratory, Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, 050568, Bucharest, Romania., Mocanu CA; 'Medical and Pharmaceutical Bionanotechnologies' Laboratory, Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, 050568, Bucharest, Romania., Safciuc F; 'Medical and Pharmaceutical Bionanotechnologies' Laboratory, Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, 050568, Bucharest, Romania., Anghelache M; 'Medical and Pharmaceutical Bionanotechnologies' Laboratory, Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, 050568, Bucharest, Romania., Deleanu M; 'Liquid and Gas Chromatography' Laboratory, Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, 050568, Bucharest, Romania., Cecoltan S; 'Medical and Pharmaceutical Bionanotechnologies' Laboratory, Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, 050568, Bucharest, Romania., Pinteala M; Centre of Advanced Research in Bionanoconjugates and Biopolymers, 'Petru Poni' Institute of Macromolecular Chemistry, 700487, Iasi, Romania., Uritu CM; Centre of Advanced Research in Bionanoconjugates and Biopolymers, 'Petru Poni' Institute of Macromolecular Chemistry, 700487, Iasi, Romania.; Advanced Centre for Research-Development in Experimental Medicine, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 700115, Iasi, Romania., Droc I; Central Military Hospital 'Dr. Carol Davila', Cardiovascular Surgery Clinic, Bucharest, Romania., Simionescu M; 'Medical and Pharmaceutical Bionanotechnologies' Laboratory, Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, 050568, Bucharest, Romania., Manduteanu I; 'Medical and Pharmaceutical Bionanotechnologies' Laboratory, Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, 050568, Bucharest, Romania., Calin M; 'Medical and Pharmaceutical Bionanotechnologies' Laboratory, Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, 050568, Bucharest, Romania.
المصدر: Materials today. Bio [Mater Today Bio] 2023 Mar 28; Vol. 20, pp. 100620. Date of Electronic Publication: 2023 Mar 28 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101757228 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-0064 (Electronic) Linking ISSN: 25900064 NLM ISO Abbreviation: Mater Today Bio Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : Elsevier Ltd., [2019]-
مستخلص: Runx2 is a key transcription factor involved in valvular interstitial cells (VIC) osteodifferentiation, a process actively entwined with the calcific aortic valve disease (CAVD). We hypothesize that a strategy intended to silence Runx2 could be a valuable novel therapeutic option for CAVD. To this intent, we aimed at (i) developing targeted nanoparticles for efficient delivery of short hairpin (sh)RNA sequences specific for Runx2 to the aortic valve employing a relevant mouse model for CAVD and (ii) investigate their therapeutic potential in osteoblast-differentiated VIC (oVIC) cultivated into a 3D scaffold. Since collagen IV was used as a target, a peptide that binds specifically to collagen IV (Cp) was conjugated to the surface of lipopolyplexes encapsulating shRNA-Runx2 (Cp-LPP/shRunx2). The results showed that Cp-LPP/shRunx2 were (i) cytocompatible; (ii) efficiently taken up by 3D-cultured oVIC; (iii) diminished the osteodifferentiation of human VIC (cultured in a 3D hydrogel-derived from native aortic root) by reducing osteogenic molecules expression, alkaline phosphatase activity, and calcium concentration; and (iv) were recruited in aortic valve leaflets in a murine model of atherosclerosis. Taken together, these data recommend Cp-LPP/shRunx2 as a novel targeted nanotherapy to block the progression of CAVD, with a good perspective to be introduced in practical use.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2023 The Authors.)
References: Int J Inflam. 2011;2011:364310. (PMID: 21826258)
Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6506-11. (PMID: 23533277)
Histol Histopathol. 2017 Mar;32(3):293-306. (PMID: 27353274)
Cardiovasc Res. 2020 Apr 1;116(5):983-994. (PMID: 31393559)
ACS Nano. 2016 May 24;10(5):5280-92. (PMID: 27100066)
Pharmaceutics. 2020 Nov 09;12(11):. (PMID: 33182380)
J Cell Mol Med. 2020 Jun;24(11):6350-6361. (PMID: 32307869)
Int J Mol Sci. 2022 Mar 30;23(7):. (PMID: 35409184)
Polymers (Basel). 2020 Nov 25;12(12):. (PMID: 33255639)
Int J Nanomedicine. 2020 Feb 10;15:901-912. (PMID: 32103945)
J Cardiovasc Magn Reson. 2008 Sep 25;10:43. (PMID: 18817557)
J Cardiovasc Pharmacol. 2015 Jul;66(1):63-71. (PMID: 25806689)
Pharmaceutics. 2019 Jan 21;11(1):. (PMID: 30669699)
Front Cardiovasc Med. 2021 Aug 12;8:714573. (PMID: 34458339)
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2213-8. (PMID: 20133865)
J Cell Physiol. 2015 Jan;230(1):16-26. (PMID: 24912145)
Diab Vasc Dis Res. 2019 Nov;16(6):562-576. (PMID: 31530180)
J Am Heart Assoc. 2017 May 5;6(5):. (PMID: 28476875)
Circ Res. 2013 Jul 5;113(2):198-208. (PMID: 23833294)
Pharmaceutics. 2020 Jun 02;12(6):. (PMID: 32498305)
Int J Biol Macromol. 2021 Aug 31;185:604-619. (PMID: 34216662)
Diab Vasc Dis Res. 2019 Jul;16(4):310-323. (PMID: 30623669)
J Mater Chem B. 2015 Mar 28;3(12):2433-2446. (PMID: 32262120)
Nanoscale. 2021 Dec 16;13(48):20451-20461. (PMID: 34817483)
Int J Cardiol. 2018 Jul 1;262:66-70. (PMID: 29605469)
Crit Rev Oral Biol Med. 1999;10(1):79-98. (PMID: 10759428)
J Immunol Res. 2015;2015:851945. (PMID: 26065007)
Sci Transl Med. 2015 Feb 18;7(275):275ra20. (PMID: 25695999)
Lancet. 2008 May 24;371(9626):1800-9. (PMID: 18502305)
Circulation. 2001 Mar 20;103(11):1522-8. (PMID: 11257079)
Front Cardiovasc Med. 2021 Oct 29;8:687210. (PMID: 34778386)
Inflammation. 2012 Jun;35(3):834-40. (PMID: 21935671)
Biomaterials. 2016 Oct;105:25-37. (PMID: 27497058)
J Mol Cell Cardiol. 2011 Mar;50(3):561-9. (PMID: 21163264)
J Biol Chem. 2011 Jul 29;286(30):26996-7010. (PMID: 21652704)
Int J Cardiol. 2013 Oct 3;168(3):2264-71. (PMID: 23452891)
Circ J. 2013;77(1):207-16. (PMID: 23001070)
Am J Cardiol. 2020 Feb 15;125(4):589-596. (PMID: 31831151)
J Cell Biochem. 2011 Oct;112(10):2987-91. (PMID: 21678468)
Nat Rev Mol Cell Biol. 2007 Oct;8(10):839-45. (PMID: 17684528)
Eur Heart J. 2017 Jul 21;38(28):2183-2191. (PMID: 28444168)
Cardiovasc Res. 2021 Nov 22;117(13):2652-2663. (PMID: 33751034)
JAMA. 1997 Mar 19;277(11):925-6. (PMID: 9062334)
Front Pharmacol. 2020 May 13;11:685. (PMID: 32477143)
ACS Appl Nano Mater. 2018 Sep 28;1(9):4927-4939. (PMID: 31867573)
Circulation. 2003 May 6;107(17):2181-4. (PMID: 12719282)
Circ Cardiovasc Genet. 2015 Dec;8(6):812-22. (PMID: 26553695)
Aging (Albany NY). 2019 Feb 11;11(4):1085-1086. (PMID: 30745466)
Diabetes. 2009 Apr;58(4):813-9. (PMID: 19136658)
فهرسة مساهمة: Keywords: Calcific aortic valve disease; Collagen IV; Lipopolyplexes; Runx2; Valvular interstitial cells; shRNA
تواريخ الأحداث: Date Created: 20230417 Latest Revision: 20230418
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10102408
DOI: 10.1016/j.mtbio.2023.100620
PMID: 37063777
قاعدة البيانات: MEDLINE
الوصف
تدمد:2590-0064
DOI:10.1016/j.mtbio.2023.100620